List of Excipients in Branded Drug FORMOTEROL FUMARATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	FORMOTEROL FUMARATE	formoterol fumarate dihydrate	0378-1631	CITRIC ACID MONOHYDRATE
Mylan Pharmaceuticals Inc	FORMOTEROL FUMARATE	formoterol fumarate dihydrate	0378-1631	SODIUM CHLORIDE
Mylan Pharmaceuticals Inc	FORMOTEROL FUMARATE	formoterol fumarate dihydrate	0378-1631	TRISODIUM CITRATE DIHYDRATE
Mylan Pharmaceuticals Inc	FORMOTEROL FUMARATE	formoterol fumarate dihydrate	0378-1631	WATER

Generic Drugs Containing FORMOTEROL FUMARATE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	formoterol fumarate	0093-4061	CITRIC ACID MONOHYDRATE
Teva Pharmaceuticals USA Inc	formoterol fumarate	0093-4061	SODIUM CHLORIDE
Teva Pharmaceuticals USA Inc	formoterol fumarate	0093-4061	SODIUM CITRATE
Teva Pharmaceuticals USA Inc	formoterol fumarate	0093-4061	WATER
Major Pharmaceuticals	formoterol fumarate dihydrate	0904-7454	CITRIC ACID MONOHYDRATE
Major Pharmaceuticals	formoterol fumarate dihydrate	0904-7454	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in FORMOTEROL FUMARATE?

# Of NDCs	Excipient
1	CITRIC ACID
13	CITRIC ACID MONOHYDRATE
14	SODIUM CHLORIDE
6	SODIUM CITRATE
8	TRISODIUM CITRATE DIHYDRATE
13	WATER

Formoterol Fumarate Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Formoterol fumarate is a mature long-acting beta2-adrenergic agonist used primarily in inhaled products. The active ingredient has limited standalone exclusivity value, but excipient systems, inhaler devices, fixed-dose combinations, propellant transitions, and performance-critical manufacturing processes continue to create commercial opportunities. The strongest opportunities are in dry-powder inhalers, low-global-warming-potential pressurized metered-dose inhalers, nebulized products, and combination products with differentiated aerosol performance.

What is the commercial status of formoterol fumarate?

Formoterol fumarate is an established small-molecule bronchodilator with approximately 12-hour duration of action. It is used in asthma and chronic obstructive pulmonary disease products, generally in combination with an inhaled corticosteroid or another long-acting bronchodilator.

Key marketed or historically marketed dosage forms include:

Product or product type	Formoterol presentation	Delivery system	Commercial relevance
Foradil Aerolizer	Formoterol fumarate inhalation capsules	Single-dose DPI	Legacy product; capsule and carrier technology
Perforomist	Formoterol fumarate inhalation solution	Nebulizer	Preservative-free unit-dose solution platform
Symbicort	Budesonide/formoterol fumarate	pMDI	Large fixed-dose combination market
Dulera	Mometasone/formoterol fumarate	pMDI	Combination asthma product
Generic formoterol products	Formoterol fumarate, usually inhaled	DPI or nebulizer	ANDA-driven competition
Triple combinations	Formoterol with inhaled corticosteroid and LAMA	pMDI or DPI	Higher-value combination market

Formoterol has no biosimilar pathway because it is a chemically synthesized small molecule. Competition proceeds through abbreviated new drug applications, 505(b)(2) applications, product-specific device pathways, and combination-product development rather than through the biologics license application framework.

What excipients are used in formoterol fumarate inhalers?

The excipient strategy depends on the inhaler platform. Excipients must support dose uniformity, aerosolization, chemical stability, device compatibility, and lung delivery. They cannot be selected solely for conventional tablet-style manufacturability.

Dry-powder inhalers

Dry-powder formoterol products commonly use lactose as a carrier. The formulation may contain:

• Lactose monohydrate as a bulk carrier
• Micronized formoterol fumarate as the active component
• Fine lactose particles to modify aerosolization
• Magnesium stearate or other surface modifiers in selected DPI systems
• Device-dependent capsule or blister materials

Lactose carrier engineering is the principal commercial opportunity in conventional formoterol DPIs. Performance depends on particle-size distribution, surface morphology, moisture content, carrier fines, drug-carrier adhesion, and detachment during inhalation.

A DPI developer can differentiate a product through:

1. Engineered lactose with controlled fines content.
2. Porous or corrugated carrier particles.
3. Low-moisture carrier systems.
4. Carrier-free or substantially carrier-reduced powders.
5. Spray-dried composite particles.
6. Excipient coatings that reduce drug adhesion during storage but permit detachment during inhalation.

The principal technical risk is a tradeoff between storage stability and aerosol dispersion. Strong drug-carrier adhesion can improve blend uniformity but reduce fine-particle dose. Weak adhesion can produce segregation and content-uniformity failures.

Pressurized metered-dose inhalers

pMDI formulations generally use a hydrofluoroalkane propellant with a small quantity of solvent or suspension aid. Examples from approved formoterol combination labels include HFA propellant systems containing ethanol, povidone, polyethylene glycol, or oleic acid, depending on the product and active ingredients (FDA, 2024a; FDA, 2024b).

Common excipient functions include:

Excipient or excipient class	Primary function
HFA-134a or related propellant	Aerosol generation and suspension medium
Ethanol	Cosolvent and valve-performance modifier
Povidone	Suspension stabilizer and particle-surface modifier
Polyethylene glycol	Wetting and formulation stabilizer
Oleic acid	Suspension aid and valve lubricant
Surfactants	Particle wetting and sedimentation control

The transition to lower-global-warming-potential propellants creates a material opportunity. HFA-152a and hydrofluoroolefin systems such as HFO-1234ze have different density, vapor pressure, solvency, flammability, and elastomer-compatibility profiles from HFA-134a. A formoterol formulation cannot be transferred between propellants by simple substitution.

Commercially relevant development work includes:

• Reformulating formoterol suspensions for HFA-152a.
• Testing ethanol concentration and valve metering performance.
• Controlling particle growth and crystal conversion.
• Requalifying canister, actuator, gasket, and valve materials.
• Demonstrating equivalent delivered dose and aerodynamic particle-size distribution.
• Reducing extractables and leachables from new propellant-contact materials.

FDA has identified inhalation products as a priority area for alternative propellants and lower environmental impact, but each new formulation requires product-specific chemistry, manufacturing, and controls data (FDA, 2023).

Nebulized solutions

Nebulized formoterol fumarate products use aqueous solutions rather than carrier-based powders or propellant suspensions. A representative commercial formulation uses sodium chloride, citrate buffer components, and water for injection, with pH control and unit-dose packaging (FDA, 2024c).

The excipient system must control:

• Osmolality
• pH
• Chemical stability
• Microbial quality
• Container compatibility
• Nebulizer residual volume
• Delivered dose across the intended nebulizer population

Preservative-free unit-dose packaging is commercially attractive because it avoids preservative-related tolerability concerns and simplifies home-use administration. Opportunities include ready-to-use ampoules, lower-fill-volume units, mesh-nebulizer compatibility, and formulations optimized for faster treatment time.

Nebulized products also create a route for patients who cannot generate sufficient inspiratory flow for a DPI. The commercial limitation is higher packaging and distribution cost, along with dependence on nebulizer performance.

What excipient strategy is strongest for formoterol fumarate?

The most defensible strategy is platform-specific rather than molecule-specific.

Platform	Highest-value excipient objective	Main development risk
DPI	Improve fine-particle delivery and dose uniformity	Moisture sensitivity and blend segregation
pMDI	Enable propellant transition and suspension stability	New propellant compatibility
Nebulizer	Optimize stability and delivered dose	Packaging and nebulizer variability
Fixed-dose combination	Prevent cross-component incompatibility	Complex aerosol and chemical interactions
Pediatric product	Improve usability and dose delivery at low inspiratory flow	Device and human-factor performance

Lactose-based DPI strategy

Lactose remains commercially practical because it has a long inhalation history and established regulatory familiarity. A developer can obtain differentiation through grade selection, milling, sieving, surface treatment, and blending process controls.

The strongest intellectual-property positions are likely to concern:

• Defined carrier particle-size distributions
• Specific ratios of coarse and fine lactose
• Moisture limits
• Carrier surface roughness
• Mixing energy and blend sequence
• Drug loading levels
• Capsule puncture and emptying performance
• Device geometry combined with the powder formulation

Carrier-free DPI strategy

Carrier-free systems may provide higher drug concentration and reduce dependence on lactose quality. Spray drying, spray-freezing, and particle-engineering methods can generate low-density particles with improved dispersibility.

Potential advantages include:

• Reduced blend segregation
• Lower excipient mass
• Better delivery at low inspiratory flow
• Compatibility with high-dose combination products
• A lactose-free product option

The barriers are higher process complexity, electrostatic charging, particle agglomeration, moisture uptake, and a more demanding inhalation toxicology and CMC package.

Low-GWP pMDI strategy

The transition from HFA-134a to lower-GWP propellants is one of the clearest medium-term opportunities. A formulation platform that preserves formoterol stability, metered-dose accuracy, plume geometry, and lung deposition can support multiple products.

Patentable elements may include the combination of:

• Formoterol fumarate particle characteristics
• Propellant composition
• Ethanol or cosolvent concentration
• Suspension stabilizer
• Canister coating
• Valve design
• Actuator orifice
• Storage conditions
• Manufacturing and filling process

The commercial value is higher when the same excipient and device architecture can support formoterol with budesonide, mometasone, glycopyrrolate, or other inhaled actives.

What formulations are protected by formoterol patents?

The original formoterol compound and early inhalation products are mature technologies. Current protection is more likely to arise from formulation, device, combination, manufacturing, and regulatory exclusivity than from the active ingredient itself.

Important claim categories include:

1. Formoterol particle-size and crystal-form specifications.
2. DPI carrier systems.
3. Metered-dose suspension compositions.
4. Low-GWP propellant formulations.
5. Nebulizer solution pH and buffer systems.
6. Fixed-dose combinations.
7. Inhaler devices and dose counters.
8. Manufacturing processes that preserve dose uniformity.
9. Use of formoterol in defined patient populations.
10. Digital adherence and connected-device systems.

The commercial value of a formulation patent depends on whether the claimed feature is necessary for product performance. A narrow excipient ratio may have limited blocking power if a generic can substitute another stabilizer. A claim covering a required aerosol-performance profile, device architecture, or combination formulation can be more difficult to design around.

When does formoterol fumarate lose exclusivity?

Formoterol fumarate itself has largely lost compound-level exclusivity in major markets. Generic entry is therefore possible for suitable dosage forms, subject to product-specific FDA requirements.

Exclusivity analysis must distinguish among:

• Active ingredient exclusivity
• Product-specific patents
• Formulation patents
• Device patents
• Method-of-use patents
• Combination-product patents
• Pediatric exclusivity
• Regulatory exclusivity attached to a specific application

For approved inhaled products, the relevant commercial barrier may be a patent listed in the FDA Orange Book, a device-related right not listed in the Orange Book, or development complexity that is not legally exclusive but raises generic costs.

The Orange Book lists approved drug products and applicable patent and exclusivity information. A formoterol competitor must review the current product-specific listings rather than rely on the age of the active ingredient alone (FDA, 2024d).

What is the Orange Book status of formoterol products?

The Orange Book is relevant to formoterol products that are approved as drug products, including inhalation solutions and fixed-dose combinations. It does not provide a complete picture of all device, manufacturing, trade-secret, or unlisted formulation barriers.

For an ANDA applicant, the principal legal questions are:

• Which patents are listed against the reference listed drug?
• Are the patents active on the expected approval date?
• Is a Paragraph IV certification available?
• Does the proposed product infringe formulation or method claims?
• Is the reference product a complex drug-device combination?
• Does the proposed device have a comparable performance profile?

A Paragraph IV certification can trigger patent litigation and a 30-month stay under the Hatch-Waxman framework if the reference-product sponsor files suit within the statutory period. The commercial risk is highest when the branded product combines an active patent with difficult device or formulation development.

Which companies are challenging formoterol products?

Generic and specialty inhalation companies are the primary challengers. The competitive field includes companies with experience in:

• DPI development
• Nebulized solutions
• pMDI manufacturing
• Complex generic products
• Combination inhalers
• Inhaler-device engineering

Large generic manufacturers may compete on established lactose-based DPI or nebulizer platforms. Specialist respiratory companies may pursue 505(b)(2) products, new devices, lower-GWP reformulations, or differentiated combination products.

The strongest competitive advantage is usually manufacturing capability rather than ownership of the formoterol molecule. Critical capabilities include micronization, low-dose blending, aerosol testing, propellant filling, valve assembly, inhalation-grade analytical methods, and device human-factors validation.

What generic entry risks exist for formoterol fumarate?

Generic entry risk is high for simple formoterol products and lower for complex inhalers.

High-risk categories for originators

• Formoterol nebulizer solutions with straightforward compositions
• Standard lactose-based DPI capsules
• Products with expired compound and formulation patents
• Products using widely available devices

Moderate-risk categories

• Fixed-dose combination inhalers
• Products with proprietary dose counters
• pMDIs requiring suspension stabilization
• Products with complex in vitro equivalence requirements

Lower near-term substitution risk

• Products using novel low-GWP propellants
• Carrier-free powders with proprietary particle engineering
• Products requiring a specific device for dose delivery
• Combination products with difficult bioequivalence pathways

Inhaled generics must establish pharmaceutical equivalence and, where required, comparable aerodynamic performance. The FDA has issued product-specific guidance for several inhaled products, reflecting the importance of dose delivery and device performance in abbreviated applications (FDA, 2024e).

What patent litigation affects formoterol products?

Historic litigation has generally centered on branded inhaler patents, fixed-dose combinations, device systems, and generic challenges rather than on the basic formoterol molecule. The most commercially relevant litigation questions concern whether:

• A generic device falls within an asserted inhaler patent.
• A formulation claim covers a substituted excipient system.
• A fixed-dose combination patent blocks a single-ingredient product.
• A method-of-use patent is enforceable against the proposed label.
• A Paragraph IV filing creates a 30-month stay.
• A settlement permits an authorized generic or delayed launch.

Settlement agreements may include licensed entry dates, authorized-generic commitments, supply rights, or restrictions tied to particular strengths and dosage forms. A generic settlement does not necessarily remove competition across all formoterol products because rights may differ between a nebulizer solution, DPI, pMDI, and fixed-dose combination.

Current litigation and settlement terms should be assessed through the Orange Book, FDA approval records, Federal Trade Commission filings, and federal court dockets. The legal exposure is product-specific.

How strong is the formoterol fumarate patent estate?

The molecule-level estate is weak because formoterol is mature. The product-level estate can still be meaningful when supported by multiple layers.

Patent layer	Relative strength	Commercial effect
Original compound patent	Low for new launches	Usually expired
Salt or crystal form	Low to moderate	Depends on enforceability and necessity
DPI carrier formulation	Moderate	Can delay simple substitution
pMDI suspension system	Moderate to strong	Difficult to replicate if performance-critical
Device architecture	Moderate to strong	May force a different device or 505(b)(2) route
Fixed-dose combination	Stronger	Can protect a branded combination after molecule expiry
Manufacturing process	Variable	Strong if process is essential and difficult to detect
Method of use	Variable	Depends on label and enforceability

The strongest commercial protection combines formulation claims, device claims, manufacturing know-how, regulatory data, and supply-chain control. A single narrow excipient claim rarely supports durable exclusivity by itself.

What commercial opportunities exist for formoterol excipients?

The most attractive opportunities are:

1. Low-GWP pMDI excipients and propellant systems

Suppliers can develop propellant-compatible suspension stabilizers, canister coatings, valve elastomers, and cosolvent systems for formoterol combination inhalers.

2. Engineered lactose for DPIs

Specialty excipient manufacturers can supply lactose grades with controlled morphology, fines distribution, moisture, and surface energy. Qualification with inhaler manufacturers can create switching costs.

3. Carrier-free spray-dried particles

Particle-engineered excipients can support lactose-free and low-flow-rate products. The opportunity is strongest in pediatric, geriatric, and severe-airflow-limitation populations.

4. Nebulizer-ready unit-dose formulations

Preservative-free, low-residual-volume presentations can compete where ease of use and treatment time matter. Packaging is part of the product strategy.

5. Excipient and device co-development

A formulation that works only with a particular actuator, capsule, blister, or nebulizer creates a defensible integrated platform. Device compatibility can be more valuable than a standalone excipient patent.

6. Combination inhaler platforms

Formoterol is commercially valuable as a component of dual and triple therapies. Excipient systems that stabilize multiple active ingredients while preserving distinct aerosol properties can support several products from one platform.

What FDA regulatory barriers apply to inhalation excipients?

FDA evaluates inhalation excipients through the context of the specific product. A substance used in oral dosage forms may not have equivalent safety precedent for chronic pulmonary administration.

Key regulatory issues include:

• Pulmonary exposure and local tolerability
• Excipient impurity profile
• Particle-size distribution
• Extractables and leachables
• Container-closure integrity
• Microbial limits
• Chemical stability
• Device compatibility
• Delivered-dose uniformity
• Aerodynamic particle-size distribution
• Nitrosamines and other potentially mutagenic impurities
• Novel propellant safety and environmental profile

The Inactive Ingredient Database can provide regulatory precedent, but precedent must match the route, dosage form, concentration, and product context. It does not automatically establish acceptability for a new inhalation use (FDA, 2024f).

How does formoterol compare with competing long-acting bronchodilators?

Formoterol has a commercially useful rapid onset relative to some other long-acting beta2 agonists and is used in both asthma and COPD combinations. Its principal competitive challenge is not another formoterol product alone. It is the broader shift toward dual and triple inhaled therapies.

Active ingredient class	Examples	Excipient opportunity
LABA	Formoterol, salmeterol, indacaterol, olodaterol	DPI carrier and pMDI suspension systems
LAMA	Tiotropium, glycopyrrolate, umeclidinium	Combination aerosol compatibility
Inhaled corticosteroid	Budesonide, mometasone, fluticasone	Chemical and physical stabilization
Triple therapy	ICS/LABA/LAMA products	Multi-active dose uniformity and device design

Formoterol remains attractive where a manufacturer already has a respiratory platform, because the same device, excipient, and manufacturing infrastructure can support a broader product portfolio.

Key Takeaways

• Formoterol fumarate has limited molecule-level exclusivity but retains value in inhaled formulations and combination products.
• Lactose carrier engineering is the most established DPI opportunity.
• Low-GWP pMDI propellant transitions offer the largest medium-term formulation opportunity.
• Nebulized, preservative-free, unit-dose products can compete through usability and delivery consistency.
• Fixed-dose combinations and device-formulation integration provide stronger protection than single-ingredient formoterol products.
• Generic entry risk is high for simple inhalation solutions and mature DPI presentations.
• The strongest patent estates combine formulation, device, process, and combination-product claims.
• Inhalation excipient development requires route-specific safety, aerosol-performance, and extractables data.
• No biosimilar risk applies; competition is governed by generic and complex-generic pathways.
• Commercial value is concentrated in platform technologies that can be reused across formoterol, corticosteroid, LAMA, and triple-therapy products.

FAQs About Formoterol Fumarate Excipient Strategy

Is lactose safe for formoterol dry-powder inhalers?

Lactose has extensive use as a DPI carrier and established inhalation precedent. Its suitability depends on grade, particle-size distribution, impurities, moisture, and product-specific performance.

Can formoterol fumarate be formulated without lactose?

Yes. Carrier-free and spray-dried powders can eliminate or reduce lactose, but they require tighter control of particle engineering, electrostatics, moisture, agglomeration, and device performance.

Which excipient is most important in a formoterol pMDI?

The propellant and suspension-stabilizer system is usually most important. Ethanol, povidone, polyethylene glycol, oleic acid, and related excipients can materially affect suspension stability, metering, plume geometry, and delivered dose.

Are formoterol inhalers eligible for automatic generic substitution?

Substitution depends on the specific FDA-approved product, therapeutic-equivalence rating, dosage form, device, and state pharmacy rules. A generic inhalation product must satisfy product-specific regulatory requirements before receiving an substitutable rating.

Does formoterol have biosimilar competition?

No. Formoterol fumarate is a chemically synthesized small molecule. Competition arises through ANDAs, 505(b)(2) applications, formulation changes, devices, and combination products rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). Metered dose inhalers: Research and development to support the transition to lower global warming potential propellants. https://www.fda.gov

2. U.S. Food and Drug Administration. (2024a). Symbicort prescribing information. AstraZeneca Pharmaceuticals LP. https://www.accessdata.fda.gov

3. U.S. Food and Drug Administration. (2024b). Dulera prescribing information. Organon LLC. https://www.accessdata.fda.gov

4. U.S. Food and Drug Administration. (2024c). Perforomist prescribing information. Viatris Inc. https://www.accessdata.fda.gov

5. U.S. Food and Drug Administration. (2024d). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Food and Drug Administration. (2024e). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development

7. U.S. Food and Drug Administration. (2024f). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm